Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: a pilot study (2016)
Type of Content
Journal ArticlePublisher
University of Canterbury. School of Health SciencesCollections
- Health: Journal Articles [151]
Authors
Nikles, J.
Mitchell, G.K.
Hardy, J.
Senior, H.
Carmont, S.A.
Schluter, P.J.
Vora, R.
Currow, D.
Yelland, M.
Abstract
Paracetamol is a useful adjunct when used in combination with “weak opioids” for chronic pain in palliative care patients with advanced cancer, however it is not certain that there is continuing benefit when used in conjunction with “strong” opioids. N-of-1 trials allowed individual treatment decisions to be made for each participant: there was no added benefit for any of the participants, although no conclusion about the added benefit of paracetamol above regular opioids was possible for the group, due to insufficient numbers recruited. Paracetamol may not provide added benefit above regular opioids; this should assessed on a case by case basis to justify the extra tablet load.
Citation
Nikles, J., Mitchell, G.K., Hardy, J., Senior, H., Carmont, S.A., Schluter, P.J., Vora, R., Currow, D., Yelland, M. (2016) Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: A pilot study. Palliative Medicine, 30(8), pp. 800-802.This citation is automatically generated and may be unreliable. Use as a guide only.
Keywords
paracetamol; n-of-1 trial; palliative care; pain; opioidsANZSRC Fields of Research
32 - Biomedical and clinical sciences::3214 - Pharmacology and pharmaceutical sciences::321402 - Clinical pharmacology and therapeutics32 - Biomedical and clinical sciences::3211 - Oncology and carcinogenesis::321104 - Cancer therapy (excl. chemotherapy and radiation therapy)
Related items
Showing items related by title, author, creator and subject.
-
Testing the effectiveness of pilocarpine drops for dry mouth in advanced cancer using aggregated n-of-1 trials: a pilot study
Nikles, J.; Mitchell, G.K.; Hardy, J.; Agar, M.; Senior, H.; Carmont, S.A.; Schluter, P.J.; Good, P.; Vora, R.; Currow, D. (University of Canterbury. School of Health Sciences, 2015)Purpose : Dry mouth is a common and troublesome symptom in palliative care. Pilocarpine is a cholinergic agent that promotes salivation. We aimed to test the effectiveness of pilocarpine drops compared to placebo, for ... -
Do pilocarpine drops help dry mouth in palliative care patients: a protocol for an aggregated series of n-of-1 trials
Nikles, J.; Mitchell, G.K.; Hardy, J.; Agar, M.; Senior, H.; Carmont, S.-A.; Schluter, P.J.; Good, P.; Vora, R.; Currow, D. (University of Canterbury. School of Health Sciences, 2013)Background: It is estimated that 39,000 Australians die from malignant disease yearly. Of these, 60% to 88% of advanced cancer patients suffer xerostomia, the subjective feeling of mouth dryness. Xerostomia has significant ... -
Model of Drug Delivery to Populations Composed of Two Cell Types.
Kuznetsov AV; Zhao D; de Monte F; Pontrelli G; Becker, Sid; ZHAO, DAN (Elsevier BV, 2021)The rate of drug delivery to cells and the subsequent rate of drug metabolism are dependent on the cell membrane permeability to the drug. In some cases, tissue may be composed of different types of cells that exhibit order ...